These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35228870)

  • 1. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
    Ros-Gañán I; Hommel M; Trigueros-Motos L; Tamarit B; Rodríguez-García E; Salas D; Pérez G; Douar A; Combal JP; Benichou B; Ferrer V; González-Aseguinolaza G
    Clin Transl Immunology; 2022; 11(2):e1375. PubMed ID: 35228870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.
    Leborgne C; Barbon E; Alexander JM; Hanby H; Delignat S; Cohen DM; Collaud F; Muraleetharan S; Lupo D; Silverberg J; Huang K; van Wittengerghe L; Marolleau B; Miranda A; Fabiano A; Daventure V; Beck H; Anguela XM; Ronzitti G; Armour SM; Lacroix-Desmazes S; Mingozzi F
    Nat Med; 2020 Jul; 26(7):1096-1101. PubMed ID: 32483358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
    Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
    J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice.
    Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H
    Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and local immune responses to intraocular AAV vector administration in non-human primates.
    Ail D; Ren D; Brazhnikova E; Nouvel-Jaillard C; Bertin S; Mirashrafi SB; Fisson S; Dalkara D
    Mol Ther Methods Clin Dev; 2022 Mar; 24():306-316. PubMed ID: 35229004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.
    Kashiwakura Y; Endo K; Ugajin A; Kikuchi T; Hishikawa S; Nakamura H; Katakai Y; Baatartsogt N; Hiramoto T; Hayakawa M; Kamoshita N; Yamazaki S; Kume A; Mori H; Sata N; Sakata Y; Muramatsu SI; Ohmori T
    Mol Ther Methods Clin Dev; 2023 Sep; 30():502-514. PubMed ID: 37693948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.
    Majowicz A; Nijmeijer B; Lampen MH; Spronck L; de Haan M; Petry H; van Deventer SJ; Meyer C; Tangelder M; Ferreira V
    Mol Ther Methods Clin Dev; 2019 Sep; 14():27-36. PubMed ID: 31276009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies.
    Haar J; Blazevic D; Strobel B; Kreuz S; Michelfelder S
    Mol Ther Methods Clin Dev; 2022 Jun; 25():360-369. PubMed ID: 35573045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo.
    Nandakumar KS; Johansson BP; Björck L; Holmdahl R
    Arthritis Rheum; 2007 Oct; 56(10):3253-60. PubMed ID: 17907170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
    Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
    J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
    Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
    Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.
    Kruzik A; Fetahagic D; Hartlieb B; Dorn S; Koppensteiner H; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():126-133. PubMed ID: 31338384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune responses to AAV gene therapy in the ocular compartment.
    Whitehead M; Osborne A; Yu-Wai-Man P; Martin K
    Biol Rev Camb Philos Soc; 2021 Aug; 96(4):1616-1644. PubMed ID: 33837614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.